Get the latest Science News and Discoveries
Using generative AI, Insilico Medicine discovers new class of Polθ Inhibitors for BRCA-deficient cancers - EurekAlert
Researchers from Insilico Medicine (“Insilico”), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, have discovered a new class of Polθ inhibitors featuring central scaffolding rings, designed using Chemistry42, the Company’s proprietary generative AI platform.
None
Or read this on Eureka Alert